Benzenesulfonamide
Showing 1 - 9 of 9
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)
Active, not recruiting
- Triple -Negative Breast Cancer
- +4 more
- Biopsy
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Aug 1, 2022
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in Buffalo (drug,
Completed
- Metastatic Carcinoma in the Liver
- +4 more
- Celecoxib
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 25, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Biopsy
- +7 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 23, 2023
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in
Suspended
- Anatomic Stage 0 Breast Cancer AJCC v8
- +18 more
- Celecoxib
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 4, 2022
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer Trial in Seattle (drug, radiation, other,
Terminated
- Recurrent Colon Carcinoma
- +5 more
- Capecitabine
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 14, 2017
Adenocarcinoma of the Prostate, Prostate Cancer Trial in Portland (Celecoxib, Placebo)
Terminated
- Adenocarcinoma of the Prostate
- Prostate Cancer
- Celecoxib
- Placebo
-
Portland, Oregon
- +1 more
Apr 26, 2017
Preclinical Validation of New Anti-melanoma Compounds
Unknown status
- Melanoma
-
Nice, FranceNice hospital
Jan 9, 2019